• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update

    5/15/25 4:50:53 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    8-K/A
    true 0001965040 0001965040 2025-03-05 2025-03-05
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K/A

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    March 5, 2025

    Date of Report (Date of earliest event reported)

     

     

    Fortrea Holdings Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-41704   92-2796441
    (State or other jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification No.)

     

    8 Moore Drive
    Durham,   North Carolina   27709
    (Address of principal executive offices)   (Zip Code)

    (Registrant’s telephone number including area code) 877-495-0816

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act.

     

    Title of Each Class

     

    Trading
    Symbol

     

    Name of exchange

    on which registered

    Common Stock, $0.001 par value   FTRE   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 10, 2025, Fortrea Holdings Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission to report that, among other things, on March 5, 2025, Erin L. Russell was elected to the Board of Directors (the “Board”) of the Company, effective as of March 7, 2025 (the “Original Form 8-K”). At the time of the Original Form 8-K filing, no decision had been made regarding on which committees Ms. Russell would serve. The Company is filing this Amendment No. 1 on Form 8-K/A to the Original Form 8-K to amend and disclose the committee assignments for Ms. Russell as required by Item 5.02 of Form 8-K.

    On May 9, 2025, as recommended by the Board’s Nominating, Corporate Governance and Compliance Committee, the Board appointed Ms. Russell to serve as a member of the Audit Committee of the Board, effective as of May 13, 2025. No other amendments, updates or modifications to the Original Form 8-K are being made by this Amendment No. 1.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Fortrea Holdings Inc.
    By:  

    /s/ Stillman Hanson

    Name:   Stillman Hanson
    Title:   General Counsel and Secretary

    Date: May 15, 2025

    Get the next $FTRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    7/24/2024$30.00Equal Weight
    Barclays
    6/6/2024$28.00Neutral
    Goldman
    More analyst ratings

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Fortrea with a new price target

      Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

      5/2/25 8:14:26 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Barclays with a new price target

      Barclays downgraded Fortrea from Equal Weight to Underweight and set a new price target of $6.00

      4/10/25 8:49:08 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Citigroup with a new price target

      Citigroup downgraded Fortrea from Buy to Neutral and set a new price target of $23.00 from $30.00 previously

      12/11/24 7:50:50 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

      DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

      2/20/25 7:00:00 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Fortrea Appoints Robert Parks as Chief Accounting Officer

      DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

      7/11/24 8:00:09 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    SEC Filings

    See more
    • Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 9:16:55 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 8-A12B filed by Fortrea Holdings Inc.

      8-A12B - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 9:12:27 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders

      8-K - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 8:42:52 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Russell Erin L

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:19:06 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Sanders Machelle

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:18:10 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Smith David Ross

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:17:01 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/24 6:28:42 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • Pike Thomas bought $248,066 worth of shares (10,000 units at $24.81), increasing direct ownership by 21% to 57,827 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      5/30/24 4:34:01 PM ET
      $FTRE
      Medical Specialities
      Health Care